Constantijn J M Halkes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/752646/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nature Medicine, 2019, 25, 603-611.	30.7	253
2	Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. Journal of Clinical Investigation, 2017, 127, 517-529.	8.2	107
3	Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood, 2014, 124, 1110-1118.	1.4	80
4	Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion. Haematologica, 2016, 101, 506-514.	3.5	38
5	CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. Frontiers in Immunology, 2018, 9, 3016.	4.8	33
6	Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transplantation, 2020, 55, 1906-1917.	2.4	33
7	Use of eltrombopag in aplastic anemia in Europe. Annals of Hematology, 2019, 98, 1341-1350.	1.8	30
8	Transplant results in adults with Fanconi anaemia. British Journal of Haematology, 2018, 180, 100-109.	2.5	25
9	Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Haematologica, 2014, 99, 751-758.	3.5	21
10	Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation—a phase I/II study. Leukemia, 2020, 34, 831-844.	7.2	21
11	αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. Blood Advances, 2021, 5, 240-249.	5.2	21
12	Impact of Tâ€cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. American Journal of Hematology, 2019, 94, 80-86.	4.1	16
13	Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients. Haematologica, 2020, 105, e13-e16.	3.5	15
14	Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Annals of Hematology, 2015, 94, 1981-1989.	1.8	12
15	Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica, 2019, 104, 1168-1175.	3.5	12
16	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Longâ€ŧerm follow up of a phase <scp>III</scp> study. American Journal of Hematology, 2020, 95, 749-758.	4.1	12
17	Relapse of Aplastic Anemia with Majority Donor Chimerism (Donor-Type Aplasia) Occurring Late after Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 480-485.	2.0	11
18	High Mutation Frequency of the <i>PIGA</i> Gene in T Cells Results in Reconstitution of GPI Anchorâ^'/CD52â^' T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell–Depleted Allogeneic Stem Cell Transplantation. Journal of Immunology, 2018, 200, 2199-2208.	0.8	9

#	Article	IF	CITATIONS
19	Allogeneic stem cell transplantation for acquired pure red cell aplasia. American Journal of Hematology, 2019, 94, E294-E296.	4.1	9
20	Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation. Transplantation, 2017, 101, 2850-2854.	1.0	8
21	Loss of the GPlâ€anchor in B″ymphoblastic leukemia by epigenetic downregulation of <i>PIGH</i> expression. American Journal of Hematology, 2019, 94, 93-102.	4.1	8
22	Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults. Cells, 2021, 10, 2905.	4.1	8
23	Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft. Transplant Immunology, 2019, 57, 101209.	1.2	7
24	special issues related to the Adlagnosis and management of acquired aplastic anemia in countries with restricted resources, aAreport on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transplantation, 2021, 56,	2.4	7
25	Low dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica. 2017. 102. e47-e51.	3.5	5
26	Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin. Haematologica, 2017, 102, e382-e383.	3.5	5
27	Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Transplantation and Cellular Therapy. 2022. 28. 105.e1-105.e7.	1.2	5
28	Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial. Blood Advances, 2022, 6, 1115-1125.	5.2	5
29	Mutation in PIGA Results in a CD52-Negative Escape Variant in a Sézary Syndrome Patient during Alemtuzumab Treatment. Journal of Investigative Dermatology, 2015, 135, 1199-1202.	0.7	4
30	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. Annals of Hematology, 2018, 97, 1785-1795.	1.8	4
31	Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation. Cytotherapy, 2021, 23, 46-56.	0.7	4
32	Shortâ€ŧerm efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia. British Journal of Haematology, 2018, 180, 459-462.	2.5	2
33	Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT. Blood, 2020, 136, 3-4.	1.4	1
34	Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT). Blood, 2020, 136, 6-7.	1.4	0